Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray.
Lisa HardingMaryia ZhdanavaAditi ShahJacqueline PesaTodor I TotevAnabelle Tardif-SamsonDominic PilonKruti JoshiPublished in: Current medical research and opinion (2024)
Regardless of health plan stringency, on average, patients exceeded US label-mandated number of antidepressant trials before esketamine initiation, which questions the need for health insurance plans PA criteria above label.
Keyphrases
- health insurance
- healthcare
- public health
- end stage renal disease
- mental health
- ejection fraction
- newly diagnosed
- affordable care act
- health information
- chronic kidney disease
- depressive symptoms
- major depressive disorder
- prognostic factors
- health promotion
- risk assessment
- sleep quality
- social media
- bipolar disorder
- patient reported